文献速递炎症性肠病

炎症性肠病患者接受生物制剂和/或免疫抑制治疗的严重感染比较风险:系统评价与荟萃分析

Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2019-03-12

该系统评价与荟萃分析检索截至2018年3月18日的文献,纳入15项观察性研究,比较炎症性肠病患者使用肿瘤坏死因子拮抗剂、非肿瘤坏死因子靶向生物制剂、托法替布及免疫抑制剂(硫嘌呤类、甲氨蝶呤)的严重感染风险。结果显示,抗肿瘤坏死因子联合免疫抑制剂、联合糖皮质激素或三药联合均较抗肿瘤坏死因子单药增加严重感染风险,而免疫抑制剂单药较肿瘤坏死因子拮抗剂单药风险更低。非肿瘤坏死因子靶向生物制剂和托法替布的比较安全性数据有限。

要点

  • 抗肿瘤坏死因子联合免疫抑制剂较单药严重感染风险升高(RR 1.19)。
  • 抗肿瘤坏死因子联合糖皮质激素较单药风险升高(RR 1.64)。
  • 免疫抑制剂单药较肿瘤坏死因子拮抗剂单药严重感染风险更低(RR 0.61)。

核心结论

  • 包含肿瘤坏死因子拮抗剂的联合治疗(尤其联用糖皮质激素)与严重感染风险升高相关。
  • 免疫抑制剂单药较肿瘤坏死因子拮抗剂单药与更低的严重感染风险相关。
  • 需要研究评估非肿瘤坏死因子靶向生物制剂和小分子药物治疗炎症性肠病的比较安全性。

研究设计与样本

  • 系统评价与荟萃分析,检索截至2018年3月18日的文献。
  • 纳入15项观察性研究(每项>500人年),仅纳入有阳性对照的研究。
  • 采用随机效应模型荟萃分析,估计相对危险度(RR)和95%CI。

主要发现

  • 与抗肿瘤坏死因子单药相比,抗肿瘤坏死因子联合免疫抑制剂严重感染风险升高(6个队列:RR 1.19,95%CI 1.03-1.37)。
  • 与抗肿瘤坏死因子单药相比,抗肿瘤坏死因子联合糖皮质激素严重感染风险升高(4个队列:RR 1.64,95%CI 1.33-2.03)。
  • 与抗肿瘤坏死因子单药相比,三药联合严重感染风险升高(2个队列:RR 1.35,95%CI 1.04-1.77)。
  • 免疫抑制剂单药较肿瘤坏死因子拮抗剂单药严重感染风险更低(7个队列:RR 0.61,95%CI 0.44-0.84)。
  • 免疫抑制剂单药较肿瘤坏死因子拮抗剂联合免疫抑制剂严重感染风险更低(2个队列:RR 0.56,95%CI 0.39-0.81)。

关键数值与推荐

  • 溃疡性结肠炎患者中,以英夫利西单抗为基础的治疗较以阿达木单抗为基础的治疗严重感染风险更低(4个队列:RR 0.57,95%CI 0.33-0.97)。
  • 克罗恩病患者中,以英夫利西单抗为基础的治疗与以阿达木单抗为基础的治疗严重感染风险无显著差异(4个队列:RR 0.91,95%CI 0.49-1.70)。
  • 研究间异质性很小。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 非肿瘤坏死因子靶向生物制剂和托法替布的比较安全性数据有限。
  • 需要研究评估非肿瘤坏死因子靶向生物制剂和小分子药物治疗炎症性肠病的比较安全性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: We performed a systematic review and meta-analysis to evaluate the comparative risk of serious infections with tumor necrosis factor (TNF) antagonists, non-TNF targeted biologics, tofacitinib, and immunosuppressive agents in patients with inflammatory bowel diseases (IBDs). METHODS: In a systematic search of publications, through March 18, 2018, we identified 15 observational studies (>500 person-years) of patients with IBD treated with TNF antagonists, non-TNF targeted biologics, tofacitinib, and/or immunosuppressive agents (thiopurines, methotrexate) that reported risk of serious infections. Only studies with active comparators were included, to allow appropriate comparative synthesis. We performed random-effects meta-analysis and estimated relative risk (RR) and 95% CIs. RESULTS: Compared with anti-TNF monotherapy, risk of serious infection increased with the combination of anti-TNF and an immunosuppressive agent (in 6 cohorts: RR, 1.19; 95% CI, 1.03-1.37), with anti-TNF and a corticosteroid (in 4 cohorts: RR, 1.64; 95% CI, 1.33-2.03), or with all 3 drugs (in 2 cohorts: RR, 1.35; 95% CI, 1.04-1.77); there was minimal heterogeneity among studies. In contrast, monotherapy with an immunosuppressive agent was associated with a lower risk of serious infections than monotherapy with a TNF antagonist (7 cohorts: RR, 0.61; 95% CI 0.44-0.84) or a TNF antagonist with an immunosuppressive agent (2 cohorts: RR, 0.56; 95% CI, 0.39-0.81). Infliximab-based therapy was associated with a lower risk of serious infections compared with adalimumab-based therapy in patients with ulcerative colitis (4 cohorts: RR, 0.57; 95% CI, 0.33-0.97), but not Crohn's disease (4 cohorts: RR, 0.91; 95% CI, 0.49-1.70). Few data were available on the comparative safety of biologic agents that do not inhibit TNF and tofacitinib. CONCLUSIONS: Combination therapies for IBD that include TNF antagonists, especially with corticosteroids, are associated with a higher risk of serious infection, whereas monotherapy with an immunosuppressive agent is associated with a lower risk, compared with monotherapy with a TNF antagonist. Studies are needed to evaluate the comparative safety of non-TNF targeted biologics and small molecules for treatment of IBD.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Singh S, Facciorusso A, Dulai PS, et al. Comparative Risk of Serious Infections With Biologic and/or Immunosuppressive Therapy in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-Analysis. Clin Gastroenterol Hepatol. 2019. PMID: 30876964. doi:10.1016/j.cgh.2019.02.044

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。